Alnylam Pharmaceuticals
NEWS
Interim results from the Phase I study presented at the Peripheral Nerve Society Annual Meeting demonstrated that the investigational therapy, NTLA-2001, greatly reduced the disease-causing protein after a single infusion.
The U.S. FDA has had a mix of announcements this week, from drug approvals to the acceptance of NDAs and INDs. Here’s a look.
BioSpace looks at five of the top investor companies that support life sciences companies across the industry.
The Rare Disease Company Coalition’s 10 founding members have brought 22 treatments to market and currently have more than 160 rare disease programs in the works.
The new year began with a fairly low level of clinical trial news. Here’s a look.
This morning, Alnylam announced vutrisiran met primary and all secondary endpoints. Here’s everything you need to know about the drug and its purpose.
Diversity and Inclusion (D&I) have been at the forefront of the national conversation during this momentous year, so BioSpace felt it imperative to reach out to employees in the life sciences industry on this subject in our wide-ranging Fall 2020 Diversity and Inclusion Survey.
Despite the constant need for social distancing, mask-wearing, and the isolation and economic uncertainty that resulted from the outbreak, there is still much to be thankful for when families gather around a virtual table to break bread and carve the turkey this year.
The end of November and beginning of December is marked by several PDUFA dates at the U.S. Food and Drug Administration (FDA). Here’s a look.
JOBS
IN THE PRESS